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Background: Limited data exist regarding management of patients with a single brain lesion with extracranial
disease due to non-small cell lung cancer (NSCLC).
Methods: Eighty-eight consecutive patients with a single brain lesion from NSCLC in the presence of extracranial
disease were treated with stereotactic radiosurgery (SRS) alone. Local control (LC), distant intracranial failure (DIF),
overall survival (OS), and toxicity were assessed. The logrank test was used to identify prognostic variables.
Results: Median OS was 10.6 months. One-year DIF was 61%; LC 89%. Treatments were delivered in 1-5 fractions to
median BED10 = 60Gy. Five patients developed radionecrosis. Factors associated with shortened OS included poor
performance status (PS) (p = 0.0002) and higher Recursive Partitioning Analysis class (p = 0.017). For patients with PS
0, median survival was 22 months. DIF was associated with systemic disease status (progressive vs. stable) (p = 0.0001), as
was BED (p = 0.021) on univariate analysis, but only systemic disease (p = 0.0008) on multivariate analysis.
Conclusions: This study identifies a patient population that may have durable intracranial control after treatment with
SRS alone. These data support the need for prospective studies to optimize patient selection for up-front SRS and to
characterize the impact of DIF on patients’ quality of life.
Keywords: Brain metastases, Non-small cell lung cancer, Palliative care, Distant intracranial failure, Stereotactic
radiosurgery, CyberKnifeBackground
Brain metastases are common, occurring in 20-40% of
cancer patients and contributing to 20% of annual cancer
deaths [1]. Brain metastases are particularly common
among patients with non-small cell lung cancer (NSCLC),
even at the time of diagnosis, accounting for approxi-
mately 18-64% of all brain metastasis diagnoses [2]. How-
ever, some of these patients will present with limited
intracranial disease, with one or few metastatic lesions.
Overall prognosis of patients with brain metastases is lim-
ited, but has been shown to vary significantly, based on* Correspondence: Marie-Adele.S.Kress@gunet.georgetown.edu
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reproduction in any medium, provided the orfactors such as tumor histology, number of lesions, patient
age and performance status [3-7].
With advances in systemic therapy, tailoring intracra-
nial radiation therapy (RT) to individual patients’ clinical
circumstances is increasingly important. Recent studies
have evaluated the role of stereotactic radiosurgery
(SRS) in combination with or instead of surgery and/or
whole brain radiation therapy (WBRT) in carefully se-
lected patient subgroups [8-10]. The goal of using SRS
as a stand-alone therapy has been to maximize local
control (LC) while minimizing toxicities and adverse im-
pact on quality of life (QOL) [11-14]. However, some pa-
tients still benefit from up-front WBRT as part of their
treatment, as demonstrated in Patchell’s study where
24% of patients treated with surgery alone had distant
intracranial recurrence only, compared to 8% whod. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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main vague, regarding optimal treatment regimens for
patients with metastatic NSCLC; as a result, SRS use re-
mains heterogeneous [15-19]. Overall, significant limita-
tions still exist regarding optimizing patient selection for
up-front SRS as a single modality, since these patients
present with heterogeneous clinical circumstances.
Historically, a limited cohort of patients with a solitary
brain lesion due to metastatic NSCLC have been treated
with surgery to achieve LC and ultimately long-term
intracranial disease-free survival [20,21]. However, in pa-
tients with single brain metastases in the presence of ac-
tive extracranial disease, LC, distant intracranial failure
(DIF) and survival are less while characterized. This pa-
tient population is important, since brain metastases are
often diagnosed in the presence of extracranial disease.
Both LC and DIF can be significant to patients’ long-
term prognosis as well as their functional status and
QOL, making the decision of which up-front RT tech-
nique(s) to select particularly important.
To better define prognosis for patients with a single
brain metastases from NSCLC and more effectively
characterize which patients are at relatively high or low
risk for distant intracranial recurrence, retrospective data
from two institutions were pooled for evaluation of clin-




This retrospective study was approved by the Institu-
tional Review Boards of both Georgetown University
and the University of North Carolina (UNC). Eighty-
eight patients were identified who were treated between
2002 and 2011, 40 of whom were treated at UNC, and
48 of whom were treated at Georgetown. All patients
had a pathologically confirmed diagnosis of non-small
cell lung cancer. Patients were included with any stage
NSCLC at initial diagnosis, but at the time of presenta-
tion with brain metastases they had to have documented
extracranial disease that was either stable or progressing.
Patients were included if they had a single brain lesion,
as confirmed by magnetic resonance imaging (MRI).
Those with more than one intracranial lesion considered
suspicious for metastasis, as documented by MRI, were
excluded. Patients’ performance statuses were estimated
both using the Karnofsky Performance Status (KPS) and
Eastern Cooperative Oncology Group (ECOG) scales, to
allow for analysis by overall performance status (PS),
Recursive Partitioning Analysis (RPA) classes and
Diagnosis-Specific Graded Prognostic Index (DS-GPA)
groups. Thirteen patients without radiographic follow-
up were included in the analysis for overall survival
(OS), but not for LC or DIF. One patient without anyfollow-up was not included in evaluation of OS, LC, or
DIF.
SBRT planning and treatment
Each patient underwent simulation in the supine pos-
ition with creation of a custom immobilization device. A
treatment planning computed tomography (CT) scan
with slices of 1-3 mm thickness was used for treat-
ment of all patients. The majority of patients also had
contrast-enhanced, thin-slice MRI fused with the CT
scan for treatment planning; the most commonly used
treatment planning sequence was magnetization-prepared
rapid acquisition with gradient echo (MPRAGE), which is
a high-resolution T1 sequence with contrast. Contrast-
enhanced CT scan was used at the discretion of the
treating physician.
Gross tumor volume (GTV) was delineated on CT
scan(s) and MRI (when applicable) after fusion in the
MultiPlan treatment planning software. Typically, a cir-
cumferential margin of 1-3 mm was added to the GTV
to create the clinical target volume (CTV), with no add-
itional expansion to form the planning target volume
(PTV). Adjacent critical structures were delineated as in-
dicated, depending on the location of the treated tumor.
All treatments were performed using the CyberKnife
system (Accuray, SunnyVale, CA) and were planned
using Multiplan treatment software. This method uses
an inverse-planning technique to generate conformal
treatment plans with avoidance of critical structures. All
treatments were delivered using 6 MV photons and were
prescribed to an isodose line that provided adequate
(>95%) coverage of the PTV. All treatments were
performed using Xsight cranial tracking. Biologic equiva-
lent dose (BED) was calculated for each fractionation
scheme, with α/β ratio assumed to be 10, according to
the following formula: BED10 = (Prescription dose) * (1+
(Dose per fraction/α/β)).
Other intracranial treatment
Patients could not have undergone other intracranial
therapy such as whole brain radiation therapy prior to
this course of SRS. Patients were included regardless of
receipt of previous systemic therapy or surgery. If pa-
tients were treated with surgery to an intracranial lesion,
then the SRS treatment targeted the intracranial opera-
tive bed.
Data collection and statistical analysis
Patients were followed clinically by their treating radiation
oncologist, neurosurgeon and/or medical oncologist after
treatment. Radiographic follow-up was completed with
contrast-enhanced MRI and was read by a specialist in
neuroradiology. Typically, first radiographic follow-up oc-
curred 1-2 months after treatment, with additional follow-




Georgetown University Hospital 48 (55%)
University of North Carolina 40 (45%)
Sex (n) (per patient)
M 71 (81%)
F 17 (19%)
























* Systemic disease present, unknown to be stable vs. progressive, in
12 patients.
** Status unknown in 3 patients.
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presented with neurologic symptoms. Radiographic follow-
up time was determined by the date on which progression
was found or the last study that demonstrated no progres-
sion. Follow-up brain PET/CT imaging was used at the
discretion of the treating physician, typically to differentiate
between recurrence and radionecrosis.
Treatment response was evaluated according to the
standard Response Evaluation Criteria in Solid Tumors
(RECIST). LC was defined as no tumor growth after
treatment. DIF was defined as the absence of any new
intracranial lesions after treatment. LC, DIF, and OS
were estimated from the date of the first fraction of SRS.
Actuarial OS, LC, and DIF were calculated using the
Kaplan-Meier method. Patients were censored at the time
of the measured event or at the time of last clinical follow-
up. The social security death index was used to corroborate
date of death. Univariate analyses were performed using
the logrank test, and multivariate analyses were performed
using Cox proportional-hazards regression.
Toxicities were evaluated according to the Common
Terminology Criteria for Adverse Events (CTCAE), Ver-
sion 4.0, with specific attention to rates of intracranial
edema and radionecrosis. Determination of radionecrosis
was made through collaboration of the treating radiation
oncologist, neurosurgeon, neuroradiologist, and clinical
findings, when appropriate.
Results
Patient and lesion characteristics
Detailed patient characteristics are presented in Table 1. A
total of 88 patients were treated, 48 (55%) at Georgetown,
and 40 at UNC (45%). The majority of the patients were
male (71%), with a median age of 65. Patients generally
had good performance status, with a median ECOG score
of 1 (Table 1). All patients had systemic disease, equally
divided among those with stable (43%) or actively
progressing (43%) disease. Twelve patients had systemic
disease, but its status as stable or progressive was un-
known. The vast majority of patients (78%) had additional
sites of metastatic disease apart from the brain, and most
patients were RPA class II, with only 4 patients in RPA
class I, and 9 patients with unknown RPA status. Sixty-
eight percent of patients were DS-GPA groups 1.5-2.5.
Variables relating to the intracranial lesions are
presented in Table 2. Notably, only 6% of patients under-
went surgery prior to SRS, and 47% of patients had re-
ceived at least one dose of chemotherapy prior to SRS
treatment. Lesions overall were small, with a median size
of 13 mm (range, 1.5-56 mm), as determined by MRI.
Dosimetric parameters, presented in Table 3, demonstra-
ted the various doses and fractionation schema used for
treatment. Although all patients were treated using the
CyberKnife system, some patients were treated in a singlefraction, while others were treated in hypofractionated
treatment plans of 2–5 fractions. The BED varied substan-
tially, with a median BED10 of 60 (range, 28–81.6).
Clinical outcomes
Overall survival (OS), local control (LC) and distant
intracranial failure (DIF) are summarized in Table 4. Of
patients alive at last follow-up, median follow-up time
was 11.1 months; median OS for the entire cohort was
10.6 months. One-year actuarial survival was 47.9%. Pa-
tients had excellent 1-year actuarial LC of 89.1%, and
1-year actuarial DIF of 61.2%.









Surgery prior to SRS 5 (6%)
Chemotherapy prior to SRS 41 (47%)
Radiographic size (MRI, mm)
Median 13
Range 1.5-56
Table 4 Clinical outcomes
Endpoint Time (months)
Median follow-up, living patients 11.1
Median survival 10.6
Median local control 41.5
Distant Intracranial Failure
Median DIF, all patients 17.3
Median DIF, progressive disease 6.2
Median DIF, stable disease Not reached
1-year outcomes % Survival
1-year actuarial OS 47.9%
1-year actuarial LC 89.1%
1-year actuarial DIF 61.2%
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status (p = 0.001) and RPA class (p = 0.017) were associ-
ated with overall survival, but DS-GPA was not
(p = 0.32). When patients were placed into three groups:
ECOG = 0; ECOG = 1-2; ECOG = 3-4, the association
persisted (p = 0.001, Figure 1). On multivariate analysis
(MVA), only ECOG persisted as a significant factor
(p = 0.036 when modeled with RPA class; p = 0.0081
when modeled without RPA class). No factors were
found to be associated with LC on either UVA or MVA.
On UVA, both BED (p = 0.021) and systemic disease
status (p = 0.001, Figure 2) were found to be associated
with DIF; only systemic disease status (p = 0.001)
persisted as a significant factor on MVA (Table 5). Using














Prescription isodose line, %
Mean 81
Median 80
Range 70-92was not associated with radiographic follow-up time
(p = 0.2701). A post-hoc power calculation to estimate
the sensitivity to detect a difference in DIF based on
systemic disease status was performed and predicted 99%
power to detect type I/II error of 0.05. A total of 11 pa-
tients (13%) underwent a salvage course of RT, either to
the previously treated lesion, a separate lesion within the
brain, or a course of WBRT.
Toxicity
Toxicities were minimal. In the acute setting, four pa-
tients experienced radionecrosis, two had intracranial
edema, two developed mild fatigue, and one developed
mild headache. None of the acute toxicities required
intervention. The four patients with acute radionecrosis
were treated in a range of 1-3 fractions and had tumors
ranging 13-23 mm in size. One additional patient devel-
oped late radionecrosis. Overall, a total of five patients
developed radionecrosis at any time point (6%). The ma-
jority of cases of radiation necrosis were asymptomatic
and were found only on radiographic imaging.Figure 1 Impact of ECOG performance status on survival.
Figure 2 Impact of systemic disease status on distant
intracranial failure.
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steroids. No patient required craniotomy for refractory
radiation necrosis.
Discussion
Our study’s novel finding is that the status of extracra-
nial disease at the time of SRS treatment predicts more
strongly than any other clinical or demographic variable
for DIF. As a result, it may be possible to more effect-
ively and prospectively identify patients who are most or
least likely to have their intracranial disease entirely con-
trolled by SRS alone. This criterion could significantly
impact patient care by optimally selecting patients for
SRS alone, while limiting the likelihood of needing sal-
vage therapy.
Stereotactic radiosurgery (SRS) is increasingly being
used for patients with brain metastases. Debate con-
tinues as to whether SRS is an appropriate first-line
treatment without the additional use of surgery or whole
brain radiation therapy (WBRT), and which endpoints,
including OS, LC, DIF, and QOL are the most significantTable 5 Multivariate analysis of distant intracranial
failure
Variable p-value Exp (b) 95% CI of Exp (b)
Systemic disease status 0.0008 9.46 2.54 – 35.14
Treatment Site 0.93 1.05 0.35 – 3.19
BED 0.13 0.31 0.069 – 1.38
Size 0.43 1.72 0.45 – 6.52
Surgery 0.19 3.51 0.53 – 23.16
Age 0.76 0.87 0.34 – 2.19
Extracranial metastases 0.49 0.59 0.13 – 2.62
ECOG Performance Status 0.59 1.18 0.64 – 2.18
Local Control 0.61 0.54 0.05 – 5.69in this patient population [16,22]. Limited data have
demonstrated that in selected patients, an initial ap-
proach that includes SRS alone is appropriate [11,16].
However, these data are tempered by the fact that in
clinical practice, many patients do not fit these trial cri-
teria, including those of advanced age, with progressive
extracranial disease, and/or poor performance status. As
a result, many gaps remain in the literature regarding
patient outcomes when using SRS alone as an initial ap-
proach. At the same time, the enthusiasm for embarking
on SRS alone as initial therapy is necessarily tempered
by the risks of development of distant intracranial dis-
ease, including risks of neurocognitive decline related to
disease progression [14,23]. Although patient-reported
outcomes (PROs)/QOL have not been studied among
many subgroups of patients with brain metastases, it is
also possible that an initial approach with SRS alone
may lead to improved PROs/QOL for some who avoid
or asymptomatically delay further intracranial treatment,
while impaired long-term PROs/QOL for others who ex-
perience recurrence and require salvage therapy in the
setting of pre-existing increase in symptoms. As a result,
identification of factors predictive of distant intracranial
recurrence is essential to refining patient selection for
SRS, WBRT, or combination therapy.
Predicting survival of patients with brain metastases
also has clinical utility. The first historical system devel-
oped for estimating patient prognosis, primarily during
an era where treatment included WBRT and/or surgery,
were the Recursive Partitioning Analysis (RPA) classes
[5]. These classes, separating patients based upon age,
status of primary tumor, and performance status, created
rough prognostic groupings that, while useful, left large,
heterogeneous groups of patients within the same cat-
egory. For example, in our study, 76% of patients were
considered RPA class II. A more modern system, the
Diagnosis-Specific Graded Prognostic Index (DS-GPA),
incorporates age, KPS, presence of extracranial metasta-
ses, and number of brain metastases to develop a score
predictive of survival [6]. However, in our series, the DS-
GPA was not found to be significantly associated with
survival, suggesting that there still exists significant het-
erogeneity, even among patients within similar prognos-
tic groups. Even more interestingly, the majority (68%)
of the patients in this study had DS-GPA scores between
1.5-2.5, which would result in a projected median sur-
vival of 6.53 months. Instead, we have demonstrated
prolonged survival of over 10 months in this carefully
selected patient group, which underscores the import-
ance of considering patients’ longer-term quality of life if
they have limited brain metastases, even in the setting of
additional adverse prognostic factors.
Although the present study has significant findings re-
garding survival and DIF, it does have several limitations
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did not occur at consistent intervals for the entire study
population, so events relating to LC and DIF may have
been discovered, in some patients, with lag-time between
development of disease and its recognition. The sample
size of this study is still relatively small, and all power
calculations were completed post-hoc due to the retro-
spective data collection and analysis. Additionally, no
prospective quality of life measures or patient-reported
outcomes were included in this study, which are of para-
mount importance in the palliative setting. Finally, pa-
tients were permitted to have additional systemic or
local therapies at the discretion of their physicians, and
preceding, concurrent, or adjuvant chemotherapy may
have impacted DIF and OS in ways that were not ana-
lyzed in this study.
Conclusions
Patients with NSCLC with a single brain metastasis in
the setting of residual extracranial disease live longer
than might be predicted by traditional prognostic algo-
rithms, including RPA class and DS-GPA. During their
prolonged survival, both LC and DIF are remarkably
high. The sole factor that increased the risk of distant
intracranial failure was progressive systemic disease at
the time of SRS. Prospective studies are needed to
optimize patient selection for up-front SRS, and to refine
follow-up schedules that minimize the impact of distant
intracranial failure on patients’ quality of life.
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